retatrutide weight loss efficacy 30 Days of — LessWrong If retatrutide isn't FDA approved

Dermatologists warn this may increase melanoma risk or make early skin cancers harder to detect

This side effect can show up in the form of brain fog, poor physical performance, irritability, forgetfulness, and more

Semaglutide Quick Facts: Drug Class: GLP-1 receptor agonist Brand Names: Ozempic (diabetes), Wegovy (weight loss), Rybelsus (oral) FDA Approval: Ozempic approved 2017, Wegovy approved 2021 Manufacturer: Novo Nordisk Dosing: Once weekly injection, starting at 0.25 mg, maximum 2.4 mg Clinical Trial Name: STEP trials (Semaglutide Treatment Effect in People with obesity) Average Weight Loss: 10-15% of body weight over 68 weeks Tirzepatide Quick Facts: Drug Class: Dual GIP/GLP-1 receptor agonist Brand Names: Mounjaro (diabetes), Zepbound (weight loss) FDA Approval: Mounjaro approved 2022, Zepbound approved 2023 Manufacturer: Eli Lilly Dosing: Once weekly injection, starting at 2.5 mg, maximum 15 mg Clinical Trial Name: SURMOUNT trials (Study to evaluate tirzepatide in obesity or overweight) Average Weight Loss: 15-22% of body weight over 72 weeks Primary Difference: The main distinction is that semaglutide activates only GLP-1 receptors, while tirzepatide activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors

Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons

Table of Contents How GLP-1 Medications Work in the Body Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of medications primarily used to manage type 2 diabetes and, more recently, obesity